Emerging from the dark side: new therapeutic applications of scheduled psychoactive substances
James, E., Robertshaw, T. L., & Westwell, A. D. | Future Medicinal Chemistry | 14 February 2019
Self-Experiments with Psychoactive Substances: A Historical Perspective
Passie, T., & Brandt, S. D. | Handbook of Experimental Pharmacology | 27 November 2018
Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.
Kivell, B., Paton, K., Kumar, N., Morani, A., Culverhouse, A., Shepherd, A., ... & Prisinzano, T. | Molecules | 11 October 2018
The epidemiology of 5-methoxy- N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. | Journal of Psychopharmacology | 30 April 2018
The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. | Journal of Psychopharmacology | 30 April 2018
Acute pharmacological effects of 2C-B in humans: An observational study
Papaseit, E., Farré, M., Perez-Maña, C., Torrens, M., Ventura, M., Pujadas, M., ... & González, D. | Frontiers in Pharmacology | 13 March 2018
Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats
Elmore, J. S., Decker, A. M., Sulima, A., Rice, K. C., Partilla, J. S., Blough, B. E., & Baumann, M. H. | Neuropharmacology | 1 March 2018
Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice
Buchborn, T., Lyons, T., & Knöpfel, T. | Frontiers in Pharmacology | 6 Februari 2018
The ‘Endless Trip’: Psychopathology and Psychopharmacology in the Hallucinogen Persisting Perception Disorder/HPPD and the NPS. A systematic review
Orsolini, L., Papanti, G. D., De Berardis, D., Guirguis, A., Corkery, J. M., & Schifano, F. | Frontiers in Psychiatry | 20 November 2017
MDA, MDMA and other mescaline-like substances in the US military’s search for a truth drug (1940s to 1960s)
Passie, T., & Benzenhöfer, U. | Drug testing and analysis | 29 August 2017
Novel Psychoactive Substances—Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs
Hassan, Z., Bosch, O. G., Singh, D., Narayanan, S., Kasinather, B. V., Seifritz, E., ... & Müller, C. P. | Frontiers in psychiatry | 18 August 2017
Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)
Luethi, D., Trachsel, D., Hoener, M. C., & Liechti, M. E. | Neuropharmacology | 15 July 2017
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)
Brandt, S. D., Kavanagh, P. V., Twamley, B., Westphal, F., Elliott, S. P., Wallach, J., ... & Halberstadt, A. L. | Drug Testing and Analysis | 5 June 2017
Genie in a blotter: A comparative study of LSD and LSD analogues’ effects and user profile
Coney, L. D., Maier, L. J., Ferris, J. A., Winstock, A. R., & Barratt, M. J. | Human Psychopharmacology: Clinical and Experimental | 18 May 2017
A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents
Vargas‐Perez, H., Grieder, T. E., Ting‐A‐Kee, R., Maal‐Bared, G., Chwalek, M., & van der Kooy, D. | European Journal of Neuroscience | 4 May 2017
LSD instead of 25I-NBOMe: The revival of LSD? A case report
Bodeau, S., Bennis, Y., Régnaut, O., Fabresse, N., Richeval, C., Humbert, L., ... & Lemaire-Hurtel, A. S. | Toxicologie Analytique et Clinique | 27 February 2017
“Being with a Buddha”: A Case Report of Methoxetamine Use in a United States Veteran with PTSD
Striebel, J. M., Nelson, E. E., & Kalapatapu, R. K. | Case reports in psychiatry | 29 January 2017
Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens
Halberstadt, A. L. | Current Topics in Behavioral Neurosciences | 18 January 2017
Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats
Noworyta-Sokołowska, K., Kamińska, K., Kreiner, G., Rogóż, Z., & Gołembiowska, K. | Neurotoxicity research | 30 November 2016
Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2’S,4’S)-lysergic acid 2,4-dimethylazetidide (LSZ)
Brandt, S. D., Kavanagh, P. V., Westphal, F., Elliott, S. P., Wallach, J., Colestock, T., ... & Halberstadt, A. L. | Drug testing and analysis | 6 June 2016
Human Pharmacology of Mephedrone in Comparison to MDMA
Papaseit, E., Pérez-Mañá, C., Mateus, J. A., Pujadas, M., Fonseca, F., Torrens, M., ... & Farré, M. | Neuropsychopharmacology | 20 May 2016
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickly, A., Moning, O., Hoener, M., Liechti, M. | European Neuropsychopharmacology | 20 May 2016
Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—Behavioural, pharmacokinetic and metabolic studies in the Wistar rat
Horsley, R. R., Lhotkova, E., Hajkova, K., Jurasek, B., Kuchar, M., & Palenicek, T. | Brain Research Bulletin | 4 May 2016
A systematic review of the effects of novel psychoactive substances ‘legal highs’ on people with severe mental illness
Gray, R., Bressington, D., Hughes, E., & Ivanecka, A. | Journal of Psychiatric and Mental Health Nursing | 1 April 2016
The History of MDMA as an Underground Drug in the United States, 1960-1979
Passie, T., & Benzenhöfer, U. | Journal of psychoactive drugs | 03 March 2016